Research
Parkinson's Disease and other movement disorders
Hope through research
The USF Health Byrd Parkinson's Disease & Movement Disorders Center evaluates and develops new medications and surgical procedures for Parkinson's Disease. Under Dr. Hauser's leadership, we conduct multiple independent and sponsored studies, pioneering advancements in treatment through research and innovation.
Annovis
NCT07284784
Brief summary: This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Status: DBS Enrolling
Study Details | NCT07284784 | A Study of Buntanetap in Participants With PD | ClinicalTrials.gov
AbbVie (ROSSINI)
NCT06107426
Brief Summary: The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in a real-world setting.
Status: Open- Not Enrolling
Neulark
Brief summary: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)
Status: Enrolling
PPMI
Brief Summary: Take the smell test challange today! Smell loss can be linked to brain disease. Researchers are studying this link to learn more about the connection. Not everyone with smell loss will develop a brain disease. Request a smell test to help scientist learn more about this risk factor.
Status: Recruiting by cohort - contact our center for details.
Bluerock
NCT06944522
Brief Summary: Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Status: Enrolling
IPX 203-401-23 (ELEVATE-PD)
NCT06765668
Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of CREXONT under real-world conditions in participants with Parkinson's disease (PD).
Status: Open- Not Enrolling
Padova
NCT04777331
Brief Description: This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
Status: Open- Not Enrolling
Pasadena
ID: NCT03100149
Brief summary: This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline.
Status: Open- Not Enrolling
Truebinding
NCT06773962
Brief summary: The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).
Status: Open- Not Enrolling
https://clinicaltrials.gov/study/NCT06773962
Cerevance
CVN424-301
Brief summary: A study to assess the efficacy of CVN424 dosed once daily, compared to placebo, for change in OFF time in Parkinson’s Disease.
Status: CLOSED
Catalpa (IPSEN)
NCT06937931
Brief summary: The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.
Status: Enrolling
TEVA
NCT06568237
Brief summary: A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study (TOPAS-MSA)
Status: Enrolling
https://clinicaltrials.gov/study/NCT06568237
LUMA
NCT05348785
Brief summary: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 (LUMA)
Status: CLOSED
Support
Our clinical trials enable us to innovate and discover new, effective treatments for Parkinson's disease and other movement disorders. The importance of our work cannot be overstated, as it brings us closer to a cure and improves the quality of life for countless patients. Donations are crucial to sustaining this vital research and ensuring ongoing progress.
To support our mission, click here or reach out to Katie Dorsey at kbdorsey@usf.edu or (813) 974-1608.